BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25711176)

  • 1. Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial.
    Hristova I; Boellaard R; Vogel W; Mottaghy F; Marreaud S; Collette S; Schöffski P; Sanfilippo R; Dewji R; van der Graaf W; Oyen WJ
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):848-57. PubMed ID: 25711176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality assessment of positron emission tomography scans: recommendations for future multicentre trials.
    de Jong EEC; van Elmpt W; Hoekstra OS; Groen HJM; Smit EF; Boellaard R; Lambin P; Dingemans AC
    Acta Oncol; 2017 Nov; 56(11):1459-1464. PubMed ID: 28830270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
    Binns DS; Pirzkall A; Yu W; Callahan J; Mileshkin L; Conti P; Scott AM; Macfarlane D; Fine BM; Hicks RJ;
    Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):642-50. PubMed ID: 21207024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation of system performance, quality control standards and adherence to international FDG-PET/CT imaging guidelines. A national survey of PET/CT operations in Austria.
    Rausch I; Bergmann H; Geist B; Schaffarich M; Hirtl A; Hacker M; Beyer T
    Nuklearmedizin; 2014; 53(6):242-8. PubMed ID: 25131649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardization and quantification in FDG-PET/CT imaging for staging and restaging of malignant disease.
    Gámez-Cenzano C; Pino-Sorroche F
    PET Clin; 2014 Apr; 9(2):117-27. PubMed ID: 25030277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma.
    Barrington SF; MacKewn JE; Schleyer P; Marsden PK; Mikhaeel NG; Qian W; Mouncey P; Patrick P; Popova B; Johnson P; Radford J; O'Doherty MJ
    Ann Oncol; 2011 Mar; 22(3):739-745. PubMed ID: 20813876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STatistically Assigned Response Criteria in Solid Tumors (STARCIST).
    Bengtsson T; Sanabria-Bohorquez SM; McCarthy TJ; Binns DS; Hicks RJ; de Crespigny AJ
    Cancer Imaging; 2015 Jul; 15(1):9. PubMed ID: 26231380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients?
    Walter F; Czernin J; Hall T; Allen-Auerbach M; Walter MA; Dunkelmann S; Federman N
    J Pediatr Hematol Oncol; 2012 Mar; 34(2):131-6. PubMed ID: 22134608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
    Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
    Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
    Mileshkin L; Hicks RJ; Hughes BG; Mitchell PL; Charu V; Gitlitz BJ; Macfarlane D; Solomon B; Amler LC; Yu W; Pirzkall A; Fine BM
    Clin Cancer Res; 2011 May; 17(10):3304-15. PubMed ID: 21364032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standardization of image quality across multiple centers by optimization of acquisition and reconstruction parameters with interim FDG-PET/CT for evaluating diffuse large B cell lymphoma.
    Daisaki H; Tateishi U; Terauchi T; Tatsumi M; Suzuki K; Shimada N; Nishida H; Numata A; Kato K; Akashi K; Harada M
    Ann Nucl Med; 2013 Apr; 27(3):225-32. PubMed ID: 23264065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
    Iagaru A; Masamed R; Chawla SP; Menendez LR; Fedenko A; Conti PS
    Clin Nucl Med; 2008 Jan; 33(1):8-13. PubMed ID: 18097248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.
    Kurland BF; Muzi M; Peterson LM; Doot RK; Wangerin KA; Mankoff DA; Linden HM; Kinahan PE
    J Nucl Med; 2016 Feb; 57(2):226-30. PubMed ID: 26493206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE.
    Song HJ; Cheng JY; Hu SL; Zhang GY; Fu Y; Zhang YJ
    Clin Radiol; 2015 Feb; 70(2):128-37. PubMed ID: 25459673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET.
    Etchebehere EC; Macapinlac HA; Gonen M; Humm K; Yeung HW; Akhurst T; Scher HI; Larson SM
    Q J Nucl Med; 2002 Jun; 46(2):122-30. PubMed ID: 12114875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [18F-FDG-PET-CT in soft tissue sarcomas: when to image?].
    Rodríguez-Alfonso B; Mucientes Rasilla J; Mitjavila Casanovas M; Cardona Arboniés J; Cubedo R
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):43-9. PubMed ID: 24094372
    [No Abstract]   [Full Text] [Related]  

  • 20. Necrosis on FDG PET/CT correlates with prognosis and mortality in sarcomas.
    Rakheja R; Makis W; Tulbah R; Skamene S; Holcroft C; Nahal A; Turcotte R; Hickeson M
    AJR Am J Roentgenol; 2013 Jul; 201(1):170-7. PubMed ID: 23789672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.